Barclays analyst Gena Wang lowered the firm’s price target on Ultragenyx (RARE) to $50 from $81 and keeps an Overweight rating on the shares. The firm dropped the price target following analysis on the setrusumab COSMIC study. It still sees an over 70% chance of a positive study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RARE:
- Ultragenyx (RARE) Earnings Call Highlights Growth and Challenges
- Ultragenyx Pharmaceutical Positioned for Success with Strategic Financing and Promising Setrusumab Trials
- Positive Outlook for Ultragenyx Pharmaceutical: Buy Rating Affirmed Amid Financial Strength and Product Growth
- Ultragenyx price target lowered to $75 from $86 at TD Cowen
- Ultragenyx Reports Q3 2025 Financial Results